Be Biopharma
Be Biopharma pioneers best-in-class B cell medicines to transform care for serious diseases, focusing on reimagining protein-based therapies for conditions like hemophilia B.
Company Overview
Be Biopharma is pioneering the development of best-in-class B cell medicines aimed at transforming care for serious diseases. Focused on reimagining protein-based therapies, the company is actively involved in the development of engineered B cell medicines that are designed to produce therapeutic proteins. These innovations have the potential to address a variety of complex medical conditions.
Focused Therapies: Hemophilia B
Be Biopharma is dedicated to advancing protein-based therapies specifically for the treatment of hemophilia B. The company's work in this area aims to provide new, effective solutions for individuals affected by this serious blood disorder. By focusing on re-engineering B cells to produce therapeutic proteins, Be Biopharma seeks to introduce groundbreaking treatments for hemophilia B patients.
Novel Treatments for Hypophosphatasia
Be Biopharma recently announced promising preclinical data for a novel B cell medicine aimed at treating Hypophosphatasia, a rare metabolic bone disease. This development highlights the company's commitment to expanding the applications of its B cell technologies to address unmet medical needs.
Scientific Contributions and Recognition
Be Biopharma's innovative work has been recognized within the scientific community, as evidenced by their presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. This platform allowed the company to share its advancements and preclinical data with experts in gene and cell therapy.
Investor Support and Financial Backing
Since its founding in October 2020, Be Biopharma has secured over $180 million in investments. This financial backing from committed investors underscores the confidence in the company's approach and its potential to revolutionize treatment options for serious diseases through B cell medicines.